Towards new therapeutic paradigms beyond symptom control in the management of inflammatory bowel diseases.
Inflammatory bowel diseases, Crohn's disease and ulcerative colitis are chronic relapsing conditions that may result in progressive bowel damage, high risk of complications, surgery and permanent disability. The conventional therapeutic approach for inflammatory bowel diseases is based mainly on symptom control. Unfortunately, a symptom-based therapeutic approach has little impact on major long-term disease outcomes. In other chronic disabling conditions such as diabetes, hypertension and rheumatoid arthritis, the development of new therapeutic approaches has led to better outcomes. In this context a "treat to target" strategy has been developed. This strategy is based on identification of high-risk patients, regular assessment of disease activity by means of objective measures, adjustment of treatment to reach the pre-defined target. A treat to target approach has recently been proposed for inflammatory bowel disease with the aim at modifying the natural history of the disease. In this review, the evidence and the limitations of the treat to target paradigm in inflammatory bowel disease are analyzed and discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Recenti progressi in medicina - 109(2018), 1 vom: 03. Jan., Seite 50-58 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Malattie infiammatorie croniche dell’intestino: perché il controllo dei sintomi non è sufficiente? |
|---|
| Beteiligte Personen: |
Festa, Stefano [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.01.2019 Date Revised 03.01.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1701/2848.28755 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281100853 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281100853 | ||
| 003 | DE-627 | ||
| 005 | 20231225030845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1701/2848.28755 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0937.xml |
| 035 | |a (DE-627)NLM281100853 | ||
| 035 | |a (NLM)29451523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Festa, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Towards new therapeutic paradigms beyond symptom control in the management of inflammatory bowel diseases. |
| 246 | 3 | 3 | |a Malattie infiammatorie croniche dell’intestino: perché il controllo dei sintomi non è sufficiente? |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2019 | ||
| 500 | |a Date Revised 03.01.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Inflammatory bowel diseases, Crohn's disease and ulcerative colitis are chronic relapsing conditions that may result in progressive bowel damage, high risk of complications, surgery and permanent disability. The conventional therapeutic approach for inflammatory bowel diseases is based mainly on symptom control. Unfortunately, a symptom-based therapeutic approach has little impact on major long-term disease outcomes. In other chronic disabling conditions such as diabetes, hypertension and rheumatoid arthritis, the development of new therapeutic approaches has led to better outcomes. In this context a "treat to target" strategy has been developed. This strategy is based on identification of high-risk patients, regular assessment of disease activity by means of objective measures, adjustment of treatment to reach the pre-defined target. A treat to target approach has recently been proposed for inflammatory bowel disease with the aim at modifying the natural history of the disease. In this review, the evidence and the limitations of the treat to target paradigm in inflammatory bowel disease are analyzed and discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Zerboni, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Aratari, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ballanti, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Papi, Claudio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 109(2018), 1 vom: 03. Jan., Seite 50-58 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2018 |g number:1 |g day:03 |g month:01 |g pages:50-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1701/2848.28755 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2018 |e 1 |b 03 |c 01 |h 50-58 | ||